CA2873650A1 - Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow - Google Patents

Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow Download PDF

Info

Publication number
CA2873650A1
CA2873650A1 CA2873650A CA2873650A CA2873650A1 CA 2873650 A1 CA2873650 A1 CA 2873650A1 CA 2873650 A CA2873650 A CA 2873650A CA 2873650 A CA2873650 A CA 2873650A CA 2873650 A1 CA2873650 A1 CA 2873650A1
Authority
CA
Canada
Prior art keywords
alpha
ketosterol
cholesten
bile acid
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873650A
Other languages
English (en)
French (fr)
Inventor
Andrea DEBARBER
Subhasish Purkayastha
Robert D. Steiner
Michal Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DH Technologies Development Pte Ltd
Oregon Health and Science University
Original Assignee
DH Technologies Development Pte Ltd
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DH Technologies Development Pte Ltd, Oregon Health and Science University filed Critical DH Technologies Development Pte Ltd
Publication of CA2873650A1 publication Critical patent/CA2873650A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • H01J49/0031—Step by step routines describing the use of the apparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G01N2333/90248—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13
    • G01N2333/90251—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13 with a definite EC number (1.14.13.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Endocrinology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2873650A 2012-05-18 2013-05-17 Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow Abandoned CA2873650A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649044P 2012-05-18 2012-05-18
US61/649,044 2012-05-18
PCT/IB2013/000961 WO2013171568A1 (en) 2012-05-18 2013-05-17 Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow

Publications (1)

Publication Number Publication Date
CA2873650A1 true CA2873650A1 (en) 2013-11-21

Family

ID=49583216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873650A Abandoned CA2873650A1 (en) 2012-05-18 2013-05-17 Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow

Country Status (6)

Country Link
US (1) US10078091B2 (https=)
EP (1) EP2850430B1 (https=)
JP (1) JP6272834B2 (https=)
CN (1) CN104603617B (https=)
CA (1) CA2873650A1 (https=)
WO (1) WO2013171568A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860418A1 (en) * 2012-01-05 2013-07-11 Dh Technologies Development Pte. Ltd. Enhancement of sensitivity and specificity of ketosteroids and keto or aldehyde containing analytes
CN105785048B (zh) * 2016-04-15 2017-07-28 同济大学 基于轻同位素近同重标记的整体蛋白质定量分析方法
CN105866429B (zh) * 2016-05-06 2017-12-15 同济大学 基于自带电荷同位素试剂的生物分子标记和定量分析方法
KR20210035812A (ko) 2018-07-24 2021-04-01 에프. 호프만-라 로슈 아게 질량 분석법용 시약
WO2023047304A1 (en) * 2021-09-22 2023-03-30 Dh Technologies Development Pte. Ltd. Ms/ms-based identification of trisulfide bonds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3029907B2 (ja) * 1991-12-20 2000-04-10 理化学研究所 抗肥満剤
JP4613299B2 (ja) 2003-01-30 2011-01-12 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド 分析物分析に関する方法、混合物、キット、および組成物
US7307169B2 (en) 2004-01-05 2007-12-11 Applera Corporation Isotopically enriched N-substituted piperazines and methods for the preparation thereof
US20060183238A1 (en) 2005-02-09 2006-08-17 Applera Corporation Amine-containing compound analysis methods
WO2007140380A2 (en) 2006-05-26 2007-12-06 Applera Corporation Tagging reagents and methods for hydroxylated compounds
GB0713463D0 (en) * 2007-07-11 2007-08-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
US8158435B2 (en) * 2007-05-04 2012-04-17 Oregon Health & Science University Tandem mass spectrometry for detecting and/or screening for conditions associated with altered sterols
WO2010141075A1 (en) * 2009-05-31 2010-12-09 Dh Technologies Development Pte. Ltd. Specific analysis of ketone and aldehyde analytes using reagent compounds labeling strategies, and mass spectrometry workflow
US8372653B2 (en) 2010-01-22 2013-02-12 Dh Technologies Development Pte. Ltd. Mass tag reagents for simultaneous quantitation and identification of small molecules

Also Published As

Publication number Publication date
JP6272834B2 (ja) 2018-01-31
EP2850430B1 (en) 2017-04-19
EP2850430A1 (en) 2015-03-25
US20150323554A1 (en) 2015-11-12
WO2013171568A1 (en) 2013-11-21
CN104603617A (zh) 2015-05-06
EP2850430A4 (en) 2016-02-10
JP2015516578A (ja) 2015-06-11
CN104603617B (zh) 2017-04-12
US10078091B2 (en) 2018-09-18

Similar Documents

Publication Publication Date Title
US12196765B2 (en) Mass spectrometry assay for congenital adrenal hyperplasia
EP3511973A1 (en) Quantitation of insulin by mass spectrometry
US20140349885A1 (en) Enhancement of sensitivity and specificity of ketosteroids and keto or aldehyde containing analytes
US20110006197A1 (en) Methods for detecting dihydrotestosterone by mass spectrometry
EP2850430B1 (en) Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow
Kamemura et al. Sample-multiplexing by derivatization using multiple analogous reagents for enhancing throughput in LC/ESI-MS/MS assay of steroids: plasma 17α-hydroxyprogesterone as an example
US8283627B2 (en) Methods for detecting dehydroepiandrosterone by mass spectrometry
HK40120889A (en) Mass spectrometry assay for congenital adrenal hyperplasia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180514

FZDE Discontinued

Effective date: 20220802